Genmab — Februar 2024

[LP90]

Godmorgen

[bibob]

God morgen.

[E_L]

Nivolumab is IgG4 PD-1 , isnt't it? and Pembrolizumab

[E_L]

not sure where you found that Sukkeralf, but would be another confirmation of GEN1042 also then if that is a new trial?

[E_L]

annual US price change for Darzalex 6.3%, Tecvayli 5.0%, Rybrevant 4.0% (Sarclisa was +2.5%, like last year when Sanofi also did another hike in the summer)

[E_L]

talking about sarclisa; they sold €103mn in Q4 for a total of €381mn full year '23

[Sukkeralf]

Ensayos Clínicos Activos | Fundación HM

Coordinamos ensayos clínicos en red para acelerar resultados y descubrimientos médicos. ¡Conoce nuestra labor!

Fundación HM (www.fundacionhm.com)

[Sukkeralf]

Scroll down to the right study

[Sukkeralf]

But maybe its the title thats wrong

[E_L]

well, it would fit Jan's comment:

af Jan Van de Winkel
GEN1056 is going to be positioned very broadly as a potential combination therapy for multiple other Genmab next generation antibody therapeutics.

[E_L]

Major bank sees positive signals in Lundbeck's MSA study despite missed endpoint https://medwatch.com/News/Pharma___Biotech/article16812127.ece

[Sukkeralf]

But why keep it a secret - others are pursuing the same…….
unless Genmab has another nice new feature.

[E_L]

don't know...

[E_L]

Circio is testing TG01 mutant RAS cancer vaccine in combination with daratumumab and nivolumab in non-small cell lung cancer (NSCLC) https://www.circio.com/en/the-first-patient-has-been-dosed-in-circios-tg01-triple-combination-study/

[havana]

Jeg har nogle 100'er GENMAB aktier fra 2009. De skal sælges i år kva min alder.
Skal jeg sælge inden årsregnskabet?

[Bella1]

Nå,nå, en god fredagsnyhed, - hvor langt skal vi så ned?

[lahn1]

Jeg håber så sandeligt at mine mabber er stegt en del inden året udgang. Ville måske sælge før Hex-CD38 H2H data i 2H-24, det kan jo gå begge veje.

[bikube]

Hvis jeg husker rigtigt, er det en 50/50 aftale, så er det da fint med Pfizer at dele med, de har muskler til at få det fremad.

[bikube]

havana - Jeg ville aldrig sælge alt på en gang, sælg evt. 20% hver anden måned, hvis du sælger alt nu, misser du måske et stort overskud.

[ProinvestorNEWS]

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastisk Cervical Cancer https://www.proinvestor.com/investornyt/1111713/tisotumab-vedotin-marketing-authorization-application-validated-by-european-medicines-agency-for-treatment-of-recurrent-or-meta